Literature DB >> 24275260

Community-acquired infections and their association with myeloid malignancies.

Glen J Titmarsh1, Mary Frances McMullin2, Charlene M McShane1, Mike Clarke1, Eric A Engels3, Lesley A Anderson4.   

Abstract

INTRODUCTION: Antigenic stimulation is a proposed aetiologic mechanism for many haematological malignancies. Limited evidence suggests that community-acquired infections may increase the risk of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). However, associations with other myeloid malignancies including chronic myeloid leukaemia (CML) and myeloproliferative neoplasms (MPNs) are unknown.
MATERIALS AND METHODS: Using the Surveillance, Epidemiology and End Result (SEER)-Medicare database, fourteen community-acquired infections were compared between myeloid malignancy patients [AML (n=8489), CML (n=3626) diagnosed 1992-2005; MDS (n=3072) and MPNs (n=2001) diagnosed 2001-2005; and controls (200,000 for AML/CML and 97,681 for MDS/MPN]. Odds ratios (ORs) and 95% confidence intervals were adjusted for gender, age and year of selection excluding infections diagnosed in the 13-month period prior to selection to reduce reverse causality.
RESULTS: Risk of AML and MDS respectively, were significantly associated with respiratory tract infections, bronchitis (ORs 1.20 [95% CI: 1.14-1.26], 1.25 [95% CI: 1.16-1.36]), influenza (ORs 1.16 [95% CI: 1.07-1.25], 1.29 [95% CI: 1.16-1.44]), pharyngitis (ORs 1.13 [95% CI: 1.06-1.21], 1.22 [95% CI: 1.11-1.35]), pneumonia (ORs 1.28 [95% CI: 1.21-1.36], 1.52 [95% CI: 1.40-1.66]), sinusitis (ORs 1.23 [95% CI: 1.16-1.30], 1.25 [95% CI: 1.15-1.36]) as was cystitis (ORs 1.13 [95% CI: 1.07-1.18], 1.26 [95% CI: 1.17-1.36]). Cellulitis (OR 1.51 [95% CI: 1.39-1.64]), herpes zoster (OR 1.31 [95% CI: 1.14-1.50]) and gastroenteritis (OR 1.38 [95% CI: 1.17-1.64]) were more common in MDS patients than controls. For CML, associations were limited to bronchitis (OR 1.21 [95% CI: 1.12-1.31]), pneumonia (OR 1.49 [95% CI: 1.37-1.62]), sinusitis (OR 1.19 [95% CI: 1.09-1.29]) and cellulitis (OR 1.43 [95% CI: 1.32-1.55]) following Bonferroni correction. Only cellulitis (OR 1.34 [95% CI: 1.21-1.49]) remained significant in MPN patients. Many infections remained elevated when more than 6 years of preceding claims data were excluded. DISCUSSION: Common community-acquired infections may be important in the malignant transformation of the myeloid lineage. Differences in the aetiology of classic MPNs and other myeloid malignancies require further exploration.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Infection; Myeloid Malignancy; SEER-Medicare

Mesh:

Year:  2013        PMID: 24275260      PMCID: PMC3943929          DOI: 10.1016/j.canep.2013.10.009

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  32 in total

1.  [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].

Authors:  Takashi Fukuhara; Yasutaka Kakinoki
Journal:  Rinsho Byori       Date:  2006-03

Review 2.  Hematopoietic stem cells and the aging hematopoietic system.

Authors:  Roi Gazit; Irving L Weissman; Derrick J Rossi
Journal:  Semin Hematol       Date:  2008-10       Impact factor: 3.851

Review 3.  The relationship between nutrition, infection, and immunity.

Authors:  L C Corman
Journal:  Med Clin North Am       Date:  1985-05       Impact factor: 5.456

4.  Underreporting of myeloid malignancies by United States cancer registries.

Authors:  Benjamin M Craig; Dana E Rollison; Alan F List; Christopher R Cogle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-11       Impact factor: 4.254

5.  Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Malin Hultcrantz; Åsa R Derolf; Ola Landgren; Lynn R Goldin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

6.  Influenza A pneumonia presenting as progressive focal infiltrates in a stem cell transplant recipient.

Authors:  John D Scott; Janet A Englund; David Myerson; Adam P Geballe
Journal:  J Clin Virol       Date:  2004-10       Impact factor: 3.168

7.  Cellulitis with leukocytopenia as an initial sign of acute promyelocytic leukemia.

Authors:  Sachiko Sakamoto; Naoki Oiso; Masakatsu Emoto; Shusuke Uchida; Ayaka Hirao; Yoichi Tatsumi; Itaru Matsumura; Akira Kawada
Journal:  Case Rep Dermatol       Date:  2012-03-01

8.  Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study.

Authors:  M E Kroll; F Murphy; K Pirie; G K Reeves; J Green; V Beral
Journal:  Br J Cancer       Date:  2012-08-09       Impact factor: 7.640

Review 9.  NK cells in healthy aging and age-associated diseases.

Authors:  Xavier Camous; Alejandra Pera; Rafael Solana; Anis Larbi
Journal:  J Biomed Biotechnol       Date:  2012-11-20

10.  Risks of myeloid malignancies in patients with autoimmune conditions.

Authors:  L A Anderson; R M Pfeiffer; O Landgren; S Gadalla; S I Berndt; E A Engels
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more
  14 in total

Review 1.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity.

Authors:  Clara Vigneron; Adrien Mirouse; Hamid Merdji; Christophe Rousseau; Clément Cousin; Fanny Alby-Laurent; Jean-Paul Mira; Jean-Daniel Chiche; Jean-François Llitjos; Frédéric Pène
Journal:  Oncoimmunology       Date:  2019-07-19       Impact factor: 8.110

3.  Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine.

Authors:  Monica Fung; Eric Jacobsen; Arnold Freedman; Daniel Prestes; Dimitrios Farmakiotis; Xiangmei Gu; Paul L Nguyen; Sophia Koo
Journal:  Clin Infect Dis       Date:  2019-01-07       Impact factor: 9.079

4.  IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.

Authors:  Lukas F Mager; Carsten Riether; Christian M Schürch; Yara Banz; Marie-Hélène Wasmer; Regula Stuber; Alexandre P Theocharides; Xiaohong Li; Yu Xia; Hirohisa Saito; Susumu Nakae; Gabriela M Baerlocher; Markus G Manz; Kathy D McCoy; Andrew J Macpherson; Adrian F Ochsenbein; Bruce Beutler; Philippe Krebs
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

Review 5.  Inflammation in Myeloid Malignancies: From Bench to Bedside.

Authors:  Eli M Soyfer; Angela G Fleischman
Journal:  J Immunother Precis Oncol       Date:  2021-07-14

Review 6.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

Review 7.  The Microenvironment in Myeloproliferative Neoplasms.

Authors:  Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Hematol Oncol Clin North Am       Date:  2020-12-09       Impact factor: 3.722

8.  Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II).

Authors:  Uwe Wollina; Gesina Hansel; Anja Baunacke; Georgi Tchernev
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-05-18

9.  Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma.

Authors:  C J K Lam; R E Curtis; G M Dores; E A Engels; N E Caporaso; A Polliack; J L Warren; H A Young; P H Levine; A F Elmi; J F Fraumeni; M A Tucker; L M Morton
Journal:  Leukemia       Date:  2015-09-15       Impact factor: 11.528

10.  Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.

Authors:  Morten Andersen; Zamra Sajid; Rasmus K Pedersen; Johanne Gudmand-Hoeyer; Christina Ellervik; Vibe Skov; Lasse Kjær; Niels Pallisgaard; Torben A Kruse; Mads Thomassen; Jesper Troelsen; Hans Carl Hasselbalch; Johnny T Ottesen
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.